Show simple item record

dc.contributor.authorTayyar, Yaman
dc.contributor.authorIdris, Adi
dc.contributor.authorVidimce, Josif
dc.contributor.authorFerreira, Danyelle Assis
dc.contributor.authorMcMillan, Nigel Aj
dc.date.accessioned2021-07-19T03:27:06Z
dc.date.available2021-07-19T03:27:06Z
dc.date.issued2021
dc.identifier.issn2156-6976
dc.identifier.urihttp://hdl.handle.net/10072/406107
dc.description.abstractHuman papilloma virus (HPV) is the main causative agent in cervical cancers. High-risk HPV cancers, including cervical cancer, are driven by major HPV oncogene, E6 and E7, which promote uncontrolled cell growth and genomic instability. We have previously shown that the presence of HPV E7 sensitizes cells to inhibition of aurora kinases (AURKs), which regulates the control of cell entry into and through mitosis. Such treatment is highly effective at eliminating early tumors and reducing large, late tumors. In addition, the presence of HPV oncogenes also sensitizes cells to inhibition of phosphoinositide 3-kinases (PI3Ks), a family of enzymes involved in cellular functions such as cell growth and proliferation. Using MLN8237 (Alisertib), an oral, selective inhibitor of AURKs, we investigated whether Alisertib treatment can improve tumor response when combined with either radiotherapy (RT) treatment or with a PI3K inhibitor, BYL719 (Alpelisib). Indeed, both RT and Alpelisib significantly improved Alisertib-mediated tumor killing, and the promising achieved results warrant further development of these combinations, and potentially translating them to the clinics.
dc.description.peerreviewedYes
dc.languageEnglish
dc.publishere-Century Publishing Corporation
dc.publisher.urihttp://www.ajcr.us/AJCR_V11N6.html
dc.relation.ispartofpagefrom3240
dc.relation.ispartofpageto3251
dc.relation.ispartofissue6
dc.relation.ispartofjournalAmerican Journal of Cancer Research
dc.relation.ispartofvolume11
dc.subject.fieldofresearchOncology and Carcinogenesis
dc.subject.fieldofresearchcode1112
dc.subject.keywordsAlisertib
dc.subject.keywordsAlpelisib
dc.subject.keywordsE7
dc.subject.keywordsHPV
dc.subject.keywordsPI3K
dc.titleAlpelisib and radiotherapy treatment enhances Alisertib-mediated cervical cancer tumor killing
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationTayyar, Y; Idris, A; Vidimce, J; Ferreira, DA; McMillan, NA, Alpelisib and radiotherapy treatment enhances Alisertib-mediated cervical cancer tumor killing, American Journal of Cancer Research, 2021, 11 (6), pp. 3240-3251
dcterms.dateAccepted2021-05-14
dcterms.licensehttps://creativecommons.org/licenses/by-nc/4.0/
dc.date.updated2021-07-18T22:40:19Z
gro.rights.copyright© The Author(s) 2021. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted, non-commercial use, distribution and reproduction in any medium, providing that the work is properly cited.
gro.hasfulltextFull Text
gro.griffith.authorVidimce, Josif
gro.griffith.authorMcMillan, Nigel
gro.griffith.authorTayyar, Yaman A.
gro.griffith.authorIdris, Adi
gro.griffith.authorAssis Ferreira, Danyelle


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record